Oculis Holding
OCS
7 hedge funds and large institutions have $23.2M invested in Oculis Holding in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
9.54% more ownership
Funds ownership: 0% → 9.54% (+9.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
+$19.9M |
| 2 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
+$5.45M |
| 3 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$544K |
| 4 |
HF
HRT Financial
New York
|
+$206K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.1K |
Top Sellers
OCS Hedge Fund Activity: Q1 2023 in Review
7 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Oculis Holding (OCS) for Q1 2023, worth a combined $23.2M.
Buyers outnumbered sellers: 7 funds opened new OCS positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Pivotal bioVenture Partners Investment Advisor, opening a new position worth an estimated $19.9M.
- 7 institutional investors held Oculis Holding (OCS) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $23.2M of Oculis Holding stock for Q1 2023.
- 7 funds opened new Oculis Holding positions in Q1 2023 and 0 closed out, a net change of +7 holders.
- The largest Oculis Holding buyer in Q1 2023 was Pivotal bioVenture Partners Investment Advisor, an estimated $19.9M added.
Based on aggregated 13F filings for Q1 2023.